Dosing and uses of Lutrepulse (gonadorelin)
Adult dosage forms and strengths
lyophilized powder for injection
- 0.8mg/vial
No Longer Available in the United States
5 mcg q90min SC/IV
Other Indications & Uses
Induction of ovulation in women with primary hypothalamic amenorrhea
Pediatric dosage forms and strengths
Not applicable
Lutrepulse (gonadorelin) adverse (side) effects
Frequency not defined
Inj site reaction
Ovarian hyperstimulation
Thrombophlebitis
Warnings
Contraindications
Hypersensitivity to gonadorelin
Ovarian cysts
Hormonally-dependent tumors
Any condition potentially exacerbated by pregnancy
Cautions
Monitor ovarian function
Possibility of multiple gestation
Should be administered only by physician familiar with reproductive medicine & pulsatile LHRH/GnRH delivery
Pregnancy and lactation
Pregnancy category: X
Lactation: not recommended
Pregnancy categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Pharmacology of Lutrepulse (gonadorelin)
Vd: 9-15 L
Half-Life, Initial: 2-10 min
Half-Life, Terminal: 10-40 min
Metabolism: to small peptides
Excretion: urine
Mechanism of action
Recombinant human LHRH (GnRH)
Administration
IV/SC Preparation
Reconstitute aseptically with 8 mL of diluent provided (NS) immediately prior to use
Shake for a few seconds
IV/SC Administration
Administer using a pulsatile pump
Set to deliver 25 or 50 mcL based upon dose selected, over a pulse period of 1 min & a pulse frequency of 90 min
